Stocktoria
Baird Medical Investment Holdings Ltd BDMD
Baird Medical Investment Holdings Ltd (BDMD) earns a Piotroski F-score of 1/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $22.5M at a -121.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -4.13 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.324 |
| Retained earnings / assets | -0.007 |
| EBIT / assets | -0.368 |
| Equity / liabilities | 0.815 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| BDMD | Baird Medical Investment Holdings Ltd | 1/9 | 0.49 | — | -39.2% |
| DRIO | DarioHealth Corp. | 3/9 | -12.4 | — | -17.3% |
| MDAI | Spectral AI, Inc. | 3/9 | -11.78 | — | -33.6% |
| SNOA | Sonoma Pharmaceuticals, Inc. | 2/9 | — | — | +36.7% |
| NEPH | NEPHROS INC | 6/9 | — | 32.8 | +32.7% |
| SRTS | Sensus Healthcare, Inc. | 4/9 | 14.36 | — | -34.3% |
| VVOS | Vivos Therapeutics, Inc. | 2/9 | — | — | +16% |
About Baird Medical Investment Holdings Ltd
Baird Medical Investment Holdings Limited, together with its subsidiaries, engages in research, development, manufacturing, and sales of microwave ablation and other medical devices in the People's Republic of China. The company offers microwave ablation apparatus and needles; and long and fine microwave ablation needles for the treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer, and breast lumps, and uterine fibroids, as well as soft tissue ablation. It sells its products through third-party distributors. Baird Medical Investment Holdings Limited was founded in 2012 and is based in Guangzhou, China.
FAQ
Is BDMD financially healthy?
Baird Medical Investment Holdings Ltd's Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does BDMD pay a dividend?
No, Baird Medical Investment Holdings Ltd does not currently pay a dividend.
How profitable is BDMD?
In FY2025, Baird Medical Investment Holdings Ltd had a net margin of -121.0% and a return on equity of -87.0%.
Is BDMD a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Baird Medical Investment Holdings Ltd: a Piotroski F-score of 1/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.